# Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/sintilimab-versus-docetaxel-as-second-line-treatment-in-advanced-or-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yuankai Shi,Lin Wu,Xinmin Yu,Puyuan Xing,Yan Wang,Jianying Zhou,Airong Wang,Jianhua Shi,Yi Hu,Ziping Wang,Guangyu An,Yong Fang,Sanyuan Sun,Caicun Zhou,Changli Wang,Feng Ye,Xingya Li,Junye Wang,Mengzhao Wang,Yunpeng Liu,Yanqiu Zhao,Ying Yuan,Jifeng Feng,Zhendong Chen,Jindong Shi,Tao Sun,Gang Wu,Yongqian Shu,Qisen Guo,Yi Zhang,Yong Song,Shucai Zhang,Yuan Chen,Wěi Li,Hongrui Niu,Wenwei Hu,Lijun Wang,Jianan Huang,Yang Zhang,Ying Cheng,Zhendong Wu,Bo Peng,Jiya Sun,Christoph Mancao,Yanqi Wang,Luyao Sun |
| Citations | 59 |
| DOI | 10.1002/cac2.12385 |
| Fields | Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cac2.12385 |
| OpenAlex ID | https://openalex.org/W4308368198 |
| PMID | 36336841 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Puyuan Xing](https://scholariq.org/researchers/puyuan-xing/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.